Overall, our findings emphasize the significance of simultaneously targeting TP53-associated lncRNAs, specifically MEG3, and linc-ROR, to modulate cell proliferation and enhance cell survival in CRC. The gene discussed is MEG3; the disease is colorectal carcinoma.